schliessen

Filtern

 

Bibliotheken

Lipid-based nanoformulation of irinotecan: dual mechanism of action allows for combination chemo/angiogenic therapy

A number of studies have outlined the antiangiogenic effects of cytotoxic agents when administered frequently at low doses. These studies suggest that the effect of the cytotoxic agent is on the vasculature within the tumor and it is assumed that there is little or negligible cytotoxicity. Liposomal... Full description

Journal Title: Nanomedicine Nov 2011, Vol.6(9), pp.1645-54
Main Author: Waterhouse, Dawn
Other Authors: Yapp, Donald , Verreault, Maite , Anantha, Malathi , Sutherland, Brent , Bally, Marcel
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 1743-5889 ; E-ISSN: 1748-6963 ; DOI: 10.2217/nnm.11.140
Link: http://search.proquest.com/docview/903477313/?pq-origsite=primo
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: proquest903477313
title: Lipid-based nanoformulation of irinotecan: dual mechanism of action allows for combination chemo/angiogenic therapy
format: Article
creator:
  • Waterhouse, Dawn
  • Yapp, Donald
  • Verreault, Maite
  • Anantha, Malathi
  • Sutherland, Brent
  • Bally, Marcel
subjects:
  • Angiogenesis Inhibitors–Administration & Dosage
  • Angiogenesis Inhibitors–Chemistry
  • Angiogenesis Inhibitors–Therapeutic Use
  • Animals–Administration & Dosage
  • Antineoplastic Agents–Chemistry
  • Antineoplastic Agents–Therapeutic Use
  • Antineoplastic Agents–Analogs & Derivatives
  • Camptothecin–Methods
  • Chemistry, Pharmaceutical–Chemistry
  • Humans–Chemistry
  • Lipids–Drug Therapy
  • Liposomes–Drug Therapy
  • Models, Biological–Drug Therapy
  • Models, Chemical–Drug Therapy
  • Neoplasms–Drug Therapy
  • Angiogenesis Inhibitors
  • Antineoplastic Agents
ispartof: Nanomedicine, Nov 2011, Vol.6(9), pp.1645-54
description: A number of studies have outlined the antiangiogenic effects of cytotoxic agents when administered frequently at low doses. These studies suggest that the effect of the cytotoxic agent is on the vasculature within the tumor and it is assumed that there is little or negligible cytotoxicity. Liposomal drug delivery systems have the ability to provide a dual mechanism of activity where tumor accumulation can deliver high local concentrations of the drug at the site of action with concomitant slow release of the drug from carriers in the blood compartment that results in antivascular effects, similar to that achieved when dosing frequently at low levels. Although this dual mechanism of activity may be linked to other lipid nanoparticle formulations of anticancer drugs, this article summarizes the evidence supporting direct (cytotoxic) and indirect (antivascular) actions of a liposomal formulation of irinotecan.
language: eng
source:
identifier: ISSN: 1743-5889 ; E-ISSN: 1748-6963 ; DOI: 10.2217/nnm.11.140
fulltext: fulltext
issn:
  • 17435889
  • 1743-5889
  • 17486963
  • 1748-6963
url: Link


@attributes
ID1715526949
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid903477313
sourceidproquest
recordidTN_proquest903477313
sourcesystemPC
pqid903477313
display
typearticle
titleLipid-based nanoformulation of irinotecan: dual mechanism of action allows for combination chemo/angiogenic therapy
creatorWaterhouse, Dawn ; Yapp, Donald ; Verreault, Maite ; Anantha, Malathi ; Sutherland, Brent ; Bally, Marcel
ispartofNanomedicine, Nov 2011, Vol.6(9), pp.1645-54
identifier
subjectAngiogenesis Inhibitors–Administration & Dosage ; Angiogenesis Inhibitors–Chemistry ; Angiogenesis Inhibitors–Therapeutic Use ; Animals–Administration & Dosage ; Antineoplastic Agents–Chemistry ; Antineoplastic Agents–Therapeutic Use ; Antineoplastic Agents–Analogs & Derivatives ; Camptothecin–Methods ; Chemistry, Pharmaceutical–Chemistry ; Humans–Chemistry ; Lipids–Drug Therapy ; Liposomes–Drug Therapy ; Models, Biological–Drug Therapy ; Models, Chemical–Drug Therapy ; Neoplasms–Drug Therapy ; Angiogenesis Inhibitors ; Antineoplastic Agents
descriptionA number of studies have outlined the antiangiogenic effects of cytotoxic agents when administered frequently at low doses. These studies suggest that the effect of the cytotoxic agent is on the vasculature within the tumor and it is assumed that there is little or negligible cytotoxicity. Liposomal drug delivery systems have the ability to provide a dual mechanism of activity where tumor accumulation can deliver high local concentrations of the drug at the site of action with concomitant slow release of the drug from carriers in the blood compartment that results in antivascular effects, similar to that achieved when dosing frequently at low levels. Although this dual mechanism of activity may be linked to other lipid nanoparticle formulations of anticancer drugs, this article summarizes the evidence supporting direct (cytotoxic) and indirect (antivascular) actions of a liposomal formulation of irinotecan.
languageeng
source
version5
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttp://search.proquest.com/docview/903477313/?pq-origsite=primo$$EView_record_in_ProQuest_(subscribers_only)
search
creatorcontrib
0Waterhouse, Dawn
1Yapp, Donald
2Verreault, Maite
3Anantha, Malathi
4Sutherland, Brent
5Bally, Marcel
titleLipid-based nanoformulation of irinotecan: dual mechanism of action allows for combination chemo/angiogenic therapy
descriptionA number of studies have outlined the antiangiogenic effects of cytotoxic agents when administered frequently at low doses. These studies suggest that the effect of the cytotoxic agent is on the vasculature within the tumor and it is assumed that there is little or negligible cytotoxicity. Liposomal drug delivery systems have the ability to provide a dual mechanism of activity where tumor accumulation can deliver high local concentrations of the drug at the site of action with concomitant slow release of the drug from carriers in the blood compartment that results in antivascular effects, similar to that achieved when dosing frequently at low levels. Although this dual mechanism of activity may be linked to other lipid nanoparticle formulations of anticancer drugs, this article summarizes the evidence supporting direct (cytotoxic) and indirect (antivascular) actions of a liposomal formulation of irinotecan.
subject
0Angiogenesis Inhibitors–Administration & Dosage
1Angiogenesis Inhibitors–Chemistry
2Angiogenesis Inhibitors–Therapeutic Use
3Animals–Administration & Dosage
4Antineoplastic Agents–Chemistry
5Antineoplastic Agents–Therapeutic Use
6Antineoplastic Agents–Analogs & Derivatives
7Camptothecin–Methods
8Chemistry, Pharmaceutical–Chemistry
9Humans–Chemistry
10Lipids–Drug Therapy
11Liposomes–Drug Therapy
12Models, Biological–Drug Therapy
13Models, Chemical–Drug Therapy
14Neoplasms–Drug Therapy
15Angiogenesis Inhibitors
16Antineoplastic Agents
general
0English
1Future Medicine Ltd
210.2217/nnm.11.140
3Medical Database
4Health & Medical Collection (Alumni edition)
5Medical Database (Alumni edition)
6ProQuest Pharma Collection
7Health & Medical Collection
8UK and Ireland Database
9ProQuest Central
10ProQuest Hospital Collection
11Hospital Premium Collection (Alumni edition)
12ProQuest Health & Medical Complete
13ProQuest Medical Library
14ProQuest Central (new)
15Health Research Premium Collection
16Health Research Premium Collection (Alumni edition)
17ProQuest Central China
18ProQuest One Academic
sourceidproquest
recordidproquest903477313
issn
017435889
11743-5889
217486963
31748-6963
rsrctypearticle
creationdate2011
addtitleNanomedicine
searchscope
01000273
11006761
21006762
31006815
41007067
51007945
61008886
71009064
81009127
91009386
1010000039
1110000047
1210000118
1310000119
1410000155
1510000156
1610000157
1710000158
1810000255
1910000256
2010000268
2110000270
2210000271
2310000300
2410000302
2510000348
2610000360
27proquest
scope
01000273
11006761
21006762
31006815
41007067
51007945
61008886
71009064
81009127
91009386
1010000039
1110000047
1210000118
1310000119
1410000155
1510000156
1610000157
1710000158
1810000255
1910000256
2010000268
2110000270
2210000271
2310000300
2410000302
2510000348
2610000360
27proquest
lsr43
01000273true
11006761true
21006762true
31006815true
41007067true
51007945true
61008886true
71009064true
81009127true
91009386true
1010000039true
1110000047true
1210000118true
1310000119true
1410000155true
1510000156true
1610000157true
1710000158true
1810000255true
1910000256true
2010000268true
2110000270true
2210000271true
2310000300true
2410000302true
2510000348true
2610000360true
startdate20111101
enddate20111101
citationpf 1645 pt 54 vol 6 issue 9
lsr30VSR-Enriched:[pqid, pages]
sort
titleLipid-based nanoformulation of irinotecan: dual mechanism of action allows for combination chemo/angiogenic therapy
authorWaterhouse, Dawn ; Yapp, Donald ; Verreault, Maite ; Anantha, Malathi ; Sutherland, Brent ; Bally, Marcel
creationdate20111101
lso0120111101
facets
frbrgroupid8509233274138758530
frbrtype5
languageeng
creationdate2011
topic
0Angiogenesis Inhibitors–Administration & Dosage
1Angiogenesis Inhibitors–Chemistry
2Angiogenesis Inhibitors–Therapeutic Use
3Animals–Administration & Dosage
4Antineoplastic Agents–Chemistry
5Antineoplastic Agents–Therapeutic Use
6Antineoplastic Agents–Analogs & Derivatives
7Camptothecin–Methods
8Chemistry, Pharmaceutical–Chemistry
9Humans–Chemistry
10Lipids–Drug Therapy
11Liposomes–Drug Therapy
12Models, Biological–Drug Therapy
13Models, Chemical–Drug Therapy
14Neoplasms–Drug Therapy
15Angiogenesis Inhibitors
16Antineoplastic Agents
collection
0Medical Database
1Health & Medical Collection (Alumni edition)
2Medical Database (Alumni edition)
3ProQuest Pharma Collection
4Health & Medical Collection
5UK and Ireland Database
6ProQuest Central
7ProQuest Hospital Collection
8Hospital Premium Collection (Alumni edition)
9ProQuest Health & Medical Complete
10ProQuest Medical Library
11ProQuest Central (new)
12Health Research Premium Collection
13Health Research Premium Collection (Alumni edition)
14ProQuest Central China
15ProQuest One Academic
prefilterarticles
rsrctypearticles
creatorcontrib
0Waterhouse, Dawn
1Yapp, Donald
2Verreault, Maite
3Anantha, Malathi
4Sutherland, Brent
5Bally, Marcel
jtitleNanomedicine
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Waterhouse
1Yapp
2Verreault
3Anantha
4Sutherland
5Bally
aufirst
0Dawn
1Donald
2Maite
3Malathi
4Brent
5Marcel
auinit1
0D.
1M.
2B.
au
0Waterhouse, Dawn
1Yapp, Donald
2Verreault, Maite
3Anantha, Malathi
4Sutherland, Brent
5Bally, Marcel
atitleLipid-based nanoformulation of irinotecan: dual mechanism of action allows for combination chemo/angiogenic therapy
jtitleNanomedicine
risdate20111101
volume6
issue9
spage1645
epage54
pages1645-1654
issn1743-5889
eissn1748-6963
formatjournal
genrearticle
ristypeJOUR
abstractA number of studies have outlined the antiangiogenic effects of cytotoxic agents when administered frequently at low doses. These studies suggest that the effect of the cytotoxic agent is on the vasculature within the tumor and it is assumed that there is little or negligible cytotoxicity. Liposomal drug delivery systems have the ability to provide a dual mechanism of activity where tumor accumulation can deliver high local concentrations of the drug at the site of action with concomitant slow release of the drug from carriers in the blood compartment that results in antivascular effects, similar to that achieved when dosing frequently at low levels. Although this dual mechanism of activity may be linked to other lipid nanoparticle formulations of anticancer drugs, this article summarizes the evidence supporting direct (cytotoxic) and indirect (antivascular) actions of a liposomal formulation of irinotecan.
copLondon
pubFuture Medicine Ltd
doi10.2217/nnm.11.140
urlhttp://search.proquest.com/docview/903477313/
date2011-11-01